Eur Rev Med Pharmacol Sci 2019; 23 (2): 539-546

DOI: 10.26355/eurrev_201901_16866

miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2

H. Fan, Y.-S. Zhang

Urology Department, Peking Union Medical College Hospital, No. 1 ShuaiFuYuan, DongCheng District, Beijing, P. R. China. zhangys_doc@163.com


OBJECTIVE: microRNAs (miRNAs) were regarded as critical participators for human cancers progression including prostate cancer (PCa) and have the potential to be used as treatment targets for cancers. Herein, we validated a tumor-suppressive miRNA, miR-490-3p, which may suppress PCa progression. Histone deacetylase 2 (HDAC2) is a protein that aberrantly expressed in several cancers. However, the role of HDAC2 in the progression of PCa has not been fully elucidated.

MATERIALS AND METHODS: Expression of miR-490-3p and HDAC2 in PCa was investigated. The effects of miR-490-3p or HDAC2 expression on PCa cell behaviors were analyzed. Association between miR-490-3p and HDAC2 was analyzed by luciferase activity reporter assay and Western blot assay.

RESULTS: We demonstrated that miR-490-3p functioned as a tumor-suppressive role in PCa progression. We found miR-490-3p expression was decreased in PCa cell lines. Down-regulation of miR-490-3p promoted the growth, migration, invasion but inhibited apoptosis of PCa cells. HDAC2 was validated as a direct target of miR-490-3p and promoted the progression of PCa cells. Further studies showed that HDAC2 could reverse the effects of miR-490-3p on growth, migration, invasion and apoptosis of PCa cells.

CONCLUSIONS: Our data highlighted the key role of miR-490-3p in the progression of PCa. Thus, miR-490-3p may be a novel cancer-specific therapeutic.

Free PDF Download

To cite this article

H. Fan, Y.-S. Zhang
miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 2
Pages: 539-546
DOI: 10.26355/eurrev_201901_16866